Megakaryocyte-specific transgene expression has proven valuable in studying thrombotic and hemostatic processes. Constitutive expression of genes, however, could result in altered phenotypes due to compensatory mechanisms or lethality. To circumvent these limitations, we have employed the tetracycline/doxycycline (Tet)-off system to conditionally overexpress genes in megakaryocytes (MKs) and platelets in vivo. We generated three transactivator transgenic lines expressing the Tet transactivator element (tTA), under the control of the megakaryocytespecific, platelet factor 4 promoter (PF4-tTA-VP16). Responder lines were simultaneously generated, each with a bidirectional minimal CMV-tTA responsive promoter driving prokaryotic ß-Galactosidase gene, as a cellular reporter, and a gene of interest (in this case, the mitotic regulator Aurora-B). A transactivator founder line that strongly expressed PF4-driven tTA-VP16 was crossbred to a responder line. The homozygous double transgenic mouse line exhibited doxycycline-dependent transgene overexpression in MKs and platelets. Using this line, platelets were conveniently indicated at sites of induced stress by ß-galactosidase staining. In addition, we confirmed our earlier report on effects of constitutive expression of Aurora-B, indicating a tight regulation at protein level and a modest effect on MK ploidy. Hence, we generated a new line, PF4-tTA-VP16 that is available for conditionally overexpressing genes of interest in the MK/platelet lineage in vivo.
Introduction
Megakaryocytes progress through distinct developmental stages, including lineage commitment, expansion, polyploidization, maturation and fragmentation into platelets 1, 2 . To investigate mechanisms that control megakaryocytic development, gene targeting is required to manipulate levels of a potential regulatory protein of interest. Over a decade ago, the rat platelet factor four (PF4) gene promoter 3 was used as a tool to specifically overexpress genes in early committed megakaryocytes in vivo. Since then, PF4 and other related promoters have been employed to examine effects of deregulating the expression of cell cycle genes, anti-apoptotic proteins, receptors, thrombosis-modulating proteins etc. on megakaryocyte/platelet development and/or activity [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . PF4-driven constitutive expression is limited, depending on the transgene used, due to occasional lethality during development or adverse effects during adulthood. For instance,
Kufrin et al. demonstrated that PF4-driven expression of urokinase-type plasminogen activator in mice exhibited a bleeding diathesis, which may have limited the potential number of founder lines that were available for analysis 10 . In addition, if a given transgene does not express due to regulatory elements within the site of genomic integration, increased numbers of founders need to be generated 13 . Tetracycline-inducible promoters and transactivating mouse lines have been employed throughout the literature to circumvent such limitations. A successful application of this system was reported for targeted expression in myeloid cells and hematopoietic progenitors in vivo [15] [16] [17] [18] , but no such study is available for cells in the megakaryocyte/platelet lineage.
As a model system for conditional and reversible overexpression of transgenes in megakaryocytes/platelets in vivo, we placed Aurora-B as well as prokaryotic ß-Galactosidase (as a reporter gene) under a bidirectional minimal promoter (creating transresponder mouse lines).
The minimal promoter can be activated by tetracycline/doxycycline-mediated removal of an enhancing protein (tTA-VP16), as originally described by 19 . The latter is generated in a different line of mice under the control of the PF4 promoter (the transactivating line). In our study, one transactivating line, which was confirmed to express the enhancer protein, was selected for crossbreeding with several transresponder lines, yielding a transgenic line, which expressed the transgene dependent upon doxycycline. ß-Gal expression was easily detected in megakaryocytes and platelets of these double transgenic lines, only upon withdrawal of doxycycline.
In summary, we demonstrated that the tetracycline/doxycycline system, in conjunction
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From with the PF4 promoter yields conditional overexpression of genes in vivo, which should be useful for targeted expression of lethality-inducing factors. The reversibility of gene expression might be an important trait when investigating effects of transformation-or thrombosispromoting genes. The transactivator line produced here needs no further development, minimizing variation due to different integration sites in potentially new lines. A designated and well examined transactivator line is now available for cross breeding with any transresponder line of interest. It can also serve as a source of bone marrow cells for conditional overexpression of retroviral-mediated infection of cultured cells with the above minimal promoter driving a gene of interest. Using this system, we were able to confirm an earlier report on constitutive overexpression of Aurora-B in megakaryocyte in vivo, indicating a tight regulation of this kinase at the protein level and a mild shift in megakaryocyte ploidy level 4 . Moreover, using this mouse line, platelets were conveniently indicated at sites of induced stress by ß-galactosidase staining.
Materials and Methods

Generation of transgenic constructs and mice
PF4-tTA-VP16 transgenic mice:
A vector containing the rat 1.1 Kb platelet factor four (PF4) 4 promoter was linearized with SacI and NheI sites and cloned into pTet-off (Cat# K1620-A, Clontech) to replace the existing CMV promoter at compatible multiple cloning sites. In the commercial construct, CMV drives the expression of the transactivator tTA fused to VP16. The existing SV40 polyA in the pTet-off vector was also replaced by the 1.7 Kb of the 3' end of human ß-globin gene (including the 3' intron and a poly A signal; base pairs 71022 to 72711 from translation start of the clone described in GenBank accession number:NT_000007) to permit a stable mRNA in transgenic mice 4 . The translated protein will not include ß-globin because the transgene contains a stop codon (described below). To prepare for injection, the construct was sequentially digested with BsmB1 and BsrB1 and the transgene was purified by electroelution.
CMV-Aurora-B/ -gal transgenic mice:
The rat Aurora-B transgene, a 1.2 Kb cDNA (GeneBank access # D89731) construct, with N-terminal FLAG-tag sequence and 3' linked -globin gene (including the 3' intron and a poly A signal) were isolated from a previously described transgenic construct 4 . This transgene was then subcloned into pBI-G vector (7.7 kb Cat # 6150-1, Clonetech) at sites Sal1 and Not1, yielding a 10.6 kb construct. This vector was linearized with Ase1 and Pst1 to exclude vector sequence, and the resulting 8 kb fragment was purified by electroelution prior to injection. Furthermore, the Flag tag at the 5'end did not affect Aurora-B protein stability, as the half-lives of the endogenous or transfected tagged protein were similar (unpublished data). Half-life determination was pursued in Y10/L8057 and HeLa cells as previously described 4 .
Transgenic production: The purified transgenes were injected into the pronucleus of mouse fertilized eggs (FVB strain, Jackson Laboratories, Bar Harbor, Maine). Positive transgenic founders were identified by Southern blot analysis on mouse-tail genomic DNA, using a radiolabeled Aurora-B probe, or tTA-VP16 probe as described previously 8 . In all analyses, agematched (6-10 week old) and sex-matched F2 and higher generation mice were used. Transgenic 
Doxycycline administration to transgenic mice
To inactivate the transactivator tTA, doxycycline, which is more stable than tetracycline (DOX, Sigma) was administered through drinking water placed in bottles wrapped with aluminum foil.
The water was supplemented with 0.5 mg/mL doxycycline (DOX) and was changed every 3-4 days to assure the activity of DOX. To induce transgene expression, DOX was removed from the drinking water 4 weeks prior to analysis. Analyses were also attempted at 2 weeks post DOX withdrawal, and transgene expression (by the transactivator line; see Figure 1 ) was detected, albeit weaker than post 4 weeks. Typically, 10-14 week old mice were analyzed.
Transgenic mRNA expression
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From Total RNA was harvested from mouse bone marrow (BM) cells (using Trizol reagent, according to the manufacturer's instructions; Invitrogen, Carlsbad, Ca). To detect transcripts of interest in rare megakaryocytes, RT-PCR (M-MLV reverse transcriptase, 1x First strain buffer, 0.5mM dNTP, 5mM DTT, 0.5U/µl RNase inhibitor, 5 µM random primers, all purchased from Invitrogen) was conducted with primer sets designed to amplify both the FLAG tag and 1.1 kb of the Aurora-B gene (PCR primer sets sense: 5' gactacaaggacgatgacgacaag 3', antisense: 5'cgatatgtctcactgtggcta 3'). To differentiate between endogenous and exogenous expression of Aurora-B, one primer was specific to the Flag sequence. The number of PCR cycles in our system was 20 for optimal transgene detection. GAPDH mRNA expression was also apparent at 20 and 22 cycles and used for normalization.
Fluorescent immunohistochemical detection of transgenic proteins
Bone marrow (BM) cells were isolated from the femurs of transgenic and control mice as previously described 8 . BM cells suspended in phosphate buffered saline (PBS) were spun down 
Immunoblot detection of transgenic proteins
Western blot analysis was performed as previously described 20 . PA). The ECL system was used for further reaction as previously described 20 .
In situ determination of ß-Galactosidase activity
The following assay was applied to both bone marrow cells and platelets. Briefly, bone marrow cells were isolated from femurs (as described above) and platelets were isolated from plasma, obtained by a low speed centrifugation of the whole blood; 5 min at 800 g (via heart puncture), by centrifugation of the plasma at 3500 rpm (Sorval biofuge pico). The pellets were resuspended in buffered fixative for 20 min, (0.5% glutaraldehyde, 0.02% NP-40, in 1X PBS without MgCl 2 ) and washed by centrifugation twice with 1X PBS. Cells were incubated with 0.2ml X-gal staining solution for 16-20 hrs at 37°C. The X-gal staining solution was freshly prepared with the following composition: 400 µg/ml X-Gal substrate (5-bromo-4-chloro-3-indolyl-ß-D-galactoside), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM magnesium chloride, all dissolved in 1X PBS). Blue precipitate (ß-galactosidase activities) can be visualized via light microscopy after mounting cells onto slides.
Platelet counts
Mouse blood collected from the tail and was diluted in IsoFlow Sheath Fluid (Beckman Coulter, Miami, FL) supplemented with 4 mM EDTA (2 µl blood in 4 ml). Blood was serially diluted 10 times and platelet numbers were counted on a Beckman Coulter Z2 counter. Alternatively, 0.5ml of blood obtained via heart puncture was collected in EDTA ready tubes (BD Biosciences,
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San Jose CA) and subjected to automated counting on the LH755 Beckman Coulter machine, Miami, FL at the Hematology Lab at Boston University School of Medicine.
Ploidy analysis of megakaryocytes
Ploidy profile analyses were performed as previously reported 4 
LPS-induced acute inflammation and tissue sections
Double transgenic mice were anaesthetized with isoflurane (40µg/g body weight) and intraperitoneally (IP) injected with lipopolysacharide (LPS) (E. coli serotype 0127;B8, Sigma) at a dosage of 60µg/g of body weight, or saline in a total volume of up to 100 µl (control), essentially as described in 21 . Mice were sacrificed 2 hours post-LPS or saline administration and perfused for 5 min. with 1X PBS, followed by 2% para-formaldeldyde for 15 minutes and finally, 1X PBS for 10 min. The livers and lungs were surgically removed immediately after fixation and subjected to staining for ß-Galactosidase as describe above. The stained organs were subsequently embedded in paraffin, thinly sectioned (5 microns) and stained with
Hematoxylin & Eosin, all as in 22 , to reveal cell types and structures.
Results and Discussion
Generation of PF4-tTA-VP16, CMV-Aurora-B/ß-gal single and double transgenic lines.
We sought to develop a system, which would allow tissue specific, conditional overexpression of transgenes in megakaryocytes and platelets in vivo. Figure 1 
illustrates the tet-on/off inducible
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From gene expression system, involving the interaction between a tissue-specific driven transgene and a minimal promoter. The tissue specific PF4 promoter drives the expression of the transactivator tTA (fused to the enhancing factor VP16). This line was cross-bred to a line carrying the tetracycline responsive element (TRE) bidirectional-CMV (minimal promoter). The use of the TRE bidirectional CMV promoter allowed the simultaneous regulation of two genes by one central TRE.
The tTA-VP16 fusion protein binds to the TRE in the absence of tetracycline/doxycycline. As a model system we chose a combination of two transgenes, including the reporter gene encoding prokaryotic ß-Galactosidase (ß-Gal) and the mitotic regulator, Aurora-B. The former was chosen for convenience of detection 3 and the latter was selected to compare results with a previously generated mouse line with constitutive expression of Aurora-B in megakaryocytes 4 .
The first goal was to generate transgenic lines in which the transactivator is specifically expressed in megakaryocytes. Three such mouse lines were generated using the PF4 promoter (PF4-tTA-VP16 # 38, 42, 54), and this was confirmed by DNA integration into the genome (Figure 2A ). Transgene expression was determined by Western blot analysis of bone marrow cells ( Figure 2B ) as well as by immunohistochemistry ( Figure 2C ). In all lines, tTA was specifically expressed in megakaryocytes ( Figure 2C ). PF4-tTA-VP16 line # 42 was chosen for further breeding as indicated below.
Several CMV-Aurora-B/ß-gal transgenic lines (# 32, 34, 41) were also generated as confirmed by Southern blot analysis of tail genomic DNA ( Figure 3A ). As expected, these lines did not express the transgene (using methods of detection as below), since they are driven by a minimal promoter that requires tTA-VP16 for activation. Because it was not possible to determine which of these CMV-Aurora-B/ß-gal lines has transgenes integrated in a chromosomal region that allows adequate expression, we used all these lines for cross breeding with the PF4-tTA-VP16 #42 line and obtained double transgenic offspring mainly with Tg #41/42 and 34/42 ( Figure 3B ).
Line 32/42 was subsequently omitted due to leaky expression of the ß-gal transgene under noninducing condition. Transgenic line #41/42 littermates were bred together to generate homozygous mice.
Inducible expression of ß-Galactosidase and generation of a mouse model for following platelet accumulation.
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From To confirm that transgene expression was inducible and reversible, we performed experiments with a double transgenic line. Homozygosity at both transgenic loci was determined by genotyping and breeding. PF4-tTA-VP16/CMV-Aurora-B/ß-gal (referred to as Tg # 41/42), a result of cross breeding PF4-tTA-VP16 #42 and CMV-Aurora-B/ß-gal line # 41, was used for analyses. As shown in Figure 4A , ß-galactosidase was expressed only upon withdrawal of doxycycline from the drinking water, which induced expression of tTA-VP16 in megakaryocytes ( Figure 3C ) and hence, activated the minimal CMV promoter (to which ß-galactosidase was linked). Interestingly, transgene expression was reversible, i.e., it could be eliminated upon readdition of doxycycline to the drinking water ( Figure 4C ). This feature should be valuable in a variety of applications, including examination of overexpressed thrombotic agents on vascular/platelet function.
Conditional and reversible transgene overexpression in platelets was also confirmed ( Figure 5 ).
The clear detection of stained platelets indicated that this mouse model would be useful in studies that require a rapid and convenient identification of platelets in organs or sites of injury.
To this end, LPS injection was used as a model system, in Tg # 41/42 mice either under Tet-on or Tet-off conditions. It has been recently reported that platelets accumulate in the livers and lungs of LPS treated animals 21 . In Figure 5B and C, platelet accumulation is clearly shown ingal stained livers, lungs and spleens, but only in mice under Tet-off conditions. No significant platelet accumulation in the above tissues was observed in mice that were not treated with LPS, compared to LPS-treated mice (data not shown). Although platelets may be detected by immunohistochemistry using fluorescent-labeled anti-CD41, it is technically difficult and time consuming to detect fluorescence in situ generated from platelet sized cells. Furthermore, tissue staining with Hematoxylin and Eosin, which is needed to identify tissue morphology, increases background fluorescence. ß-Gal staining in the above mouse model provides an additional means to clearly detect platelets within tissues.
Inducible expression of Aurora-B and bone marrow analysis.
Bone marrow cells derived from Tg # 41/42 mice treated with and without doxycycline, were subjected to immunohistochemistry with anti-Aurora-B, as was pursued for ß-galactosidase. In contrast to a high level expression of the latter throughout the cell ( Figure 4A ), Aurora-B was not detected in large recognizable megakaryocytes (surveyed over 200 megakaryocytes; data not shown), although the transgenic mRNA was readily detectable (Figure 6 ). This phenotype correlates with the one reported earlier, involving constitutive expression of Aurora-B in megakaryocytes of transgenic mice 4 , i.e., Aurora-B typically peaks at mid mitosis, and this tightly regulated protein is not concomitantly elevated upon overexpression of its mRNA. In accordance, there was no change in platelet level in the induced mice compared to control (Figure 7 ). The change in ploidy level was small ( Figure 7B ), as also previously reported 4 .
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